Homepage
Author:
Edgewise Therapeutics
Posted Date:
March 10, 2026
Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up
Edgewise Therapeutics
March 10, 2026
Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026
Edgewise Therapeutics
March 4, 2026
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference
Edgewise Therapeutics
March 3, 2026
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics
March 2, 2026
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs
Edgewise Therapeutics
February 26, 2026
Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026
Edgewise Therapeutics
February 8, 2026
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics
February 2, 2026
